FcγRIIb expression in early stage chronic lymphocytic leukemia

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 2008;22:211–219.
   PubMed Web of Science ®Google Scholar
• Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2:945–956.
   PubMed Web of Science ®Google Scholar
• Efremov DG, Gobessi S, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev. 2007;7:102–108.
   PubMed Web of Science ®Google Scholar
• Packham G, Krysov S, Allen A, et al. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica. 2014;99:1138–1148.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313–4320.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Doody GM, Dempsey PW, Fearon DT. Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Curr Opin Immunol. 1996;8:378–382.
   PubMed Web of Science ®Google Scholar
• Li DH, Tung JW, Tarner IH, et al. CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes. J Immunol. 2006;176:5321–5328.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24:19–28.
   PubMed Web of Science ®Google Scholar
• Gamberale R, Geffner JR, Giordano M. Immune complexes and apoptosis in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43:251–255.
   PubMed Web of Science ®Google Scholar
• Mackay M, Stanevsky A, Wang T, et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med. 2006;203:2157–2164.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.
   PubMed Web of Science ®Google Scholar
• Phillips NE, Parker DC. Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis. J Immunol. 1984;132:627–632.
   PubMed Web of Science ®Google Scholar
• Brown KS, Blair D, Reid SD, et al. FcgammaRIIb-mediated negative regulation of BCR signalling is associated with the recruitment of the MAPkinase-phosphatase, Pac-1, and the 3′-inositol phosphatase, PTEN. Cell Signal. 2004;16:71–80.
   PubMed Web of Science ®Google Scholar
• Ashman RF, Peckham D, Stunz LL. Fc receptor off-signal in the B cell involves apoptosis. J Immunol. 1996;157:5–11.
   PubMed Web of Science ®Google Scholar
• Bijsterbosch MK, Klaus GG. Crosslinking of surface immunoglobulin and Fc receptors on B lymphocytes inhibits stimulation of inositol phospholipid breakdown via the antigen receptors. J Exp Med. 1985;162:1825–1836.
   PubMed Web of Science ®Google Scholar
• Pearse RN, Kawabe T, Bolland S, et al. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity. 1999;10:753–760.
   PubMed Web of Science ®Google Scholar
• Ono M, Okada H, Bolland S, et al. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell. 1997;90:293–301.
   PubMed Web of Science ®Google Scholar
• Phillips NE, Parker DC. Fc-dependent inhibition of mouse B cell activation by whole anti-mu antibodies. J Immunol. 1983;130:602–606.
   PubMed Web of Science ®Google Scholar
• Baerenwaldt A, Lux A, Danzer H, et al. Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo. Proc Natl Acad Sci USA. 2011;108:18772–18777.
   PubMed Web of Science ®Google Scholar
• Horton HM, Chu SY, Ortiz EC, et al. Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011;186:4223–4233.
   PubMed Web of Science ®Google Scholar
• Lim SH, Vaughan AT, Ashton-Key M, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118:2530–2540.
   PubMed Web of Science ®Google Scholar
• Gamberale R, Geffner JR, Sanjurjo J, et al. Expression of Fcgamma receptors type II (FcgammaRII) in chronic lymphocytic leukemia B cells. Blood. 2003;102:2698–2699.
   PubMed Web of Science ®Google Scholar
• Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002;99:4087–4093.
   PubMed Web of Science ®Google Scholar
• Gamberale R, Fernandez-Calotti P, Sanjurjo J, et al. Signaling capacity of FcgammaRII isoforms in B-CLL cells. Leuk Res. 2005;29:1277–1284.
   PubMed Web of Science ®Google Scholar
• Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112:188–195.
   PubMed Web of Science ®Google Scholar
• Damle RN, Calissano C, Chiorazzi N. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol. 2010;23:33–45.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Veri MC, Gorlatov S, Li H, et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology. 2007;121:392–404.
   PubMed Web of Science ®Google Scholar
• Rankin CT, Veri MC, Gorlatov S, et al. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood. 2006;108:2384–2391.
   PubMed Web of Science ®Google Scholar
• Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177–1184.
   PubMed Web of Science ®Google Scholar
• Bulian P, Gaidano G, Del Poeta G, et al. CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target. Future Oncol. 2008;4:355–358.
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893–901.
   PubMed Web of Science ®Google Scholar
• Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011;96:752–761.
   PubMed Web of Science ®Google Scholar
• Wilson TJ, Fuchs A, Colonna M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol. 2012;188:4741–4745.
   PubMed Web of Science ®Google Scholar
• Rabinovitch N, Gelfand EW. Expression of functional activating and inhibitory Fcgamma receptors on human B cells. Int Arch Allergy Immunol. 2004;133:285–294.
   PubMed Web of Science ®Google Scholar
• Calissano C, Damle RN, Hayes G, et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood. 2009;114:4832–4842.
   PubMed Web of Science ®Google Scholar
• Malavasi F, Deaglio S, Damle R, et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118:3470–3478.
   PubMed Web of Science ®Google Scholar
• Zupo S, Massara R, Dono M, et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood. 2000;95:1199–1206.
   PubMed Web of Science ®Google Scholar
• Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood. 1996;88:1365–1374.
   PubMed Web of Science ®Google Scholar
• Lanham S, Hamblin T, Oscier D, et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:1087–1093.
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Vaisitti T, Benedetti D, et al. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia. 2012;26:1301–1312.
   PubMed Web of Science ®Google Scholar
• Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013;13:578–591.
   PubMed Web of Science ®Google Scholar